eprintid: 10064636 rev_number: 26 eprint_status: archive userid: 608 dir: disk0/10/06/46/36 datestamp: 2019-01-03 17:35:22 lastmod: 2021-10-18 22:33:03 status_changed: 2019-01-03 17:35:22 type: article metadata_visibility: show creators_name: Ashton, NJ creators_name: Schoell, M creators_name: Heurling, K creators_name: Gkanatsiou, E creators_name: Portelius, E creators_name: Hoeglund, K creators_name: Brinkmalm, G creators_name: Hye, A creators_name: Blennow, K creators_name: Zetterberg, H title: Update on biomarkers for amyloid pathology in Alzheimer's disease ispublished: pub divisions: UCL divisions: B02 divisions: C07 divisions: D07 divisions: F86 keywords: Aβ, Alzheimer's disease, amyloid-β, biomarkers, blood-based biomarkers, cerebrospinal fluid, dementia, positron emission tomography note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. abstract: At the center of Alzheimer's disease pathogenesis is the aberrant aggregation of amyloid-β (Aβ) into oligomers, fibrils and plaques. Effective monitoring of Aβ deposition directly in patients is essential to assist anti-Aβ therapeutics in target engagement and participant selection. In the advent of approved anti-Aβ therapeutics, biomarkers will become of fundamental importance in initiating treatments having disease modifying effects at the earliest stage. Two well-established Aβ biomarkers are widely utilized: Aβ-binding ligands for positron emission tomography and immunoassays to measure Aβ42 in cerebrospinal fluid. In this review, we will discuss the current clinical, diagnostic and research state of biomarkers for Aβ pathology. Furthermore, we will explore the current application of blood-based markers to assess Aβ pathology. date: 2018-07-01 date_type: published publisher: FUTURE MEDICINE LTD official_url: http://doi.org/10.2217/bmm-2017-0433 oa_status: green full_text_type: other language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1564597 doi: 10.2217/bmm-2017-0433 lyricists_name: Scholl, Michael lyricists_name: Zetterberg, Henrik lyricists_id: MSCHO84 lyricists_id: HZETT94 actors_name: Waragoda Vitharana, Nimal actors_id: NWARR44 actors_role: owner full_text_status: public publication: Biomarkers in Medicine volume: 12 number: 7 pagerange: 799-812 pages: 14 issn: 1752-0371 citation: Ashton, NJ; Schoell, M; Heurling, K; Gkanatsiou, E; Portelius, E; Hoeglund, K; Brinkmalm, G; ... Zetterberg, H; + view all <#> Ashton, NJ; Schoell, M; Heurling, K; Gkanatsiou, E; Portelius, E; Hoeglund, K; Brinkmalm, G; Hye, A; Blennow, K; Zetterberg, H; - view fewer <#> (2018) Update on biomarkers for amyloid pathology in Alzheimer's disease. Biomarkers in Medicine , 12 (7) pp. 799-812. 10.2217/bmm-2017-0433 <https://doi.org/10.2217/bmm-2017-0433>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10064636/1/Zetterberg_AshtonBiomarkMed.pdf